A new trading day began on Monday, with Mainz Biomed N.V (NASDAQ: MYNZ) stock price down -9.45% from the previous day of trading, before settling in for the closing price of $0.22. MYNZ’s price has ranged from $0.19 to $1.79 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 25.92% annually for the last half of the decade. Meanwhile, its annual earnings per share averaged 63.58%. With a float of $51.09 million, this company’s outstanding shares have now reached $64.04 million.
In terms of profitability, gross margin is 57.44%, operating margin of -3123.32%, and the pretax margin is -3057.88%.
Mainz Biomed N.V (MYNZ) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Diagnostics & Research Industry. The insider ownership of Mainz Biomed N.V is 20.22%, while institutional ownership is 0.30%.
Mainz Biomed N.V (MYNZ) Latest Financial update
In its latest quarterly report, released on 12/31/2023, the company reported earnings of -18 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -8.0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 63.58% per share during the next fiscal year.
Mainz Biomed N.V (NASDAQ: MYNZ) Trading Performance Indicators
Here are Mainz Biomed N.V’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.64, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.23 in one year’s time.
Technical Analysis of Mainz Biomed N.V (MYNZ)
Let’s dig in a bit further. During the last 5-days, its volume was 5.22 million. That was better than the volume of 1.37 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 50.93%. Additionally, its Average True Range was 0.04.
During the past 100 days, Mainz Biomed N.V’s (MYNZ) raw stochastic average was set at 5.96%, which indicates a significant decrease from 10.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 158.75% in the past 14 days, which was higher than the 142.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2537, while its 200-day Moving Average is $0.5496. However, in the short run, Mainz Biomed N.V’s stock first resistance to watch stands at $0.2155. Second resistance stands at $0.2317. The third major resistance level sits at $0.2495. If the price goes on to break the first support level at $0.1815, it is likely to go to the next support level at $0.1637. The third support level lies at $0.1475 if the price breaches the second support level.
Mainz Biomed N.V (NASDAQ: MYNZ) Key Stats
With a market capitalization of 10.96 million, the company has a total of 12,010K Shares Outstanding. Currently, annual sales are 900 K while annual income is -26,300 K. The company’s previous quarter sales were 210 K while its latest quarter income was -5,180 K.
